John C.M. Farquhar Sells 12,837 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 12,837 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total transaction of $290,886.42. Following the completion of the transaction, the chief executive officer owned 581,450 shares of the company’s stock, valued at approximately $13,175,657. The trade was a 2.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total value of $619,552.52.

Heartflow Stock Down 6.4%

Shares of HTFL stock traded down $1.42 during mid-day trading on Thursday, hitting $20.79. The company’s stock had a trading volume of 1,420,147 shares, compared to its average volume of 1,325,991. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22. The business has a 50-day moving average price of $27.83 and a 200 day moving average price of $30.76.

Institutional Investors Weigh In On Heartflow

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the fourth quarter valued at approximately $27,000. TFC Financial Management Inc. purchased a new stake in shares of Heartflow during the 3rd quarter worth approximately $40,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow in the 4th quarter valued at $45,000. Legal & General Group Plc purchased a new position in shares of Heartflow in the 3rd quarter valued at $59,000. Finally, Strs Ohio acquired a new stake in Heartflow during the 4th quarter worth $99,000.

Analyst Upgrades and Downgrades

HTFL has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company started coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective on the stock. Stifel Nicolaus lifted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $40.00 target price on shares of Heartflow in a research note on Monday. Finally, JPMorgan Chase & Co. increased their price target on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Heartflow has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.